Xbrane Biopharma AB (publ) (XBRANE.ST)

SEK 0.16

(-3.53%)

Market Cap (In SEK)

250.83 Million

Revenue (In SEK)

238.72 Million

Net Income (In SEK)

-388.17 Million

Avg. Volume

11.41 Million

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.1262-10.9
PE
-
EPS
-
Beta Value
0.993
ISIN
SE0007789409
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Martin Amark
Employee Count
-
Website
https://www.xbrane.com
Ipo Date
2016-02-03
Details
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.